BAY 383444
Alternative Names: BAY-383444Latest Information Update: 19 May 2003
At a glance
- Originator Bayer
- Class Antineoplastics; Camptothecins; Glycoconjugates
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 19 May 2003 No development reported - Phase-I for Cancer in USA (unspecified route)
- 23 Aug 2000 Phase-I clinical trials for Cancer in USA (Unknown route)
- 15 Mar 2000 Preclinical development for Cancer in USA (Unknown route)